Phospho-GAB1 (Tyr627) Antibody

What is GAB1 and what role does phosphorylation at Tyr627 play in cellular signaling?

GAB1 (GRB2-associated-binding protein 1) is an adapter protein that plays a crucial role in intracellular signaling cascades triggered by activated receptor-type kinases. It's involved in multiple signaling pathways, including FGFR1 signaling, epidermal growth factor receptor (EGFR), insulin receptor (INSR), and the MET/HGF-signaling pathway .

The phosphorylation of GAB1 at Tyr627 is specifically essential for SHP2 association and MAPK pathway activation. Research has demonstrated that phosphorylation of Tyr-627 and Tyr-659 in GAB1 is critical for SHP2 binding, while phosphorylation at different sites (Tyr-447, -472, and -589) is required for binding to the p85 subunit of PI3K and subsequent AKT signaling . This differential phosphorylation allows GAB1 to serve as a signaling hub that coordinates multiple downstream pathways.

What applications are phospho-GAB1 (Tyr627) antibodies validated for?

Commercially available phospho-GAB1 (Tyr627) antibodies have been validated for several laboratory applications:

• Western Blot (WB): Most antibodies are validated for detecting phospho-GAB1 (Tyr627) in denatured protein samples .

• Immunocytochemistry/Immunofluorescence (ICC/IF): Several antibodies can be used for cellular localization studies .

• ELISA: Cell-based ELISA kits are available for high-throughput screening of phospho-GAB1 (Tyr627) expression .

• Immunohistochemistry (IHC): Some antibodies have been successfully used for detecting phospho-GAB1 (Tyr627) in tissue sections, as demonstrated in studies of lung carcinomas in transgenic mice .

When selecting an antibody, researchers should verify specific validation data for their experimental system and application.

What is the molecular weight of phospho-GAB1 protein in Western blot analysis?

The molecular weight of phospho-GAB1 protein detected by antibodies varies slightly between sources:

• Approximately 110 kDa is reported by some manufacturers

• 77 kDa (calculated) is mentioned in other references

This variation may be due to differences in post-translational modifications, splice variants, or experimental conditions. When running Western blots, it's advisable to include positive controls and to be aware that migration patterns might differ from the theoretical molecular weight.

How should I optimize Western blot protocols for phospho-GAB1 (Tyr627) detection?

For optimal detection of phospho-GAB1 (Tyr627) by Western blot:

• Sample preparation: Use phosphatase inhibitors in lysis buffers to preserve phosphorylation status.

• Antibody dilution: Most manufacturers recommend 1/500 to 1/1000 dilutions for Western blot applications .

• Controls: Include both positive controls (EGF-treated cells show increased phosphorylation at Tyr627) and negative controls (untreated cells) .

• Protein loading: Load 20-40 μg of total protein per lane.

• Membrane blocking: Use BSA-based blocking buffers rather than milk, as milk contains phosphoproteins that may interfere with phospho-specific antibody binding.

Evidence from published data shows that EGF treatment of HUVEC cells significantly increases phospho-GAB1 (Tyr627) signal compared to untreated controls .

What cell models and stimulation protocols are appropriate for studying GAB1 Tyr627 phosphorylation?

Several cell models have been successfully used to study GAB1 Tyr627 phosphorylation:

• HeLa cells: Validated for immunofluorescence studies with phospho-GAB1 (Tyr627) antibodies .

• HUVEC cells: Show increased GAB1 Tyr627 phosphorylation upon EGF treatment .

• BEAS2B cells: Used for studying ERBB2 mutant-induced GAB1 phosphorylation .

• T47D cells: Employed in survival studies related to GAB1 phosphorylation .

• H1781 lung cancer cells: Used to investigate GAB1's role in proliferation .

For stimulation protocols:

• EGF treatment effectively induces GAB1 phosphorylation

• Growth factor starvation followed by acute stimulation (5-30 minutes) provides good signal-to-noise ratio

• Expression of constitutively active kinases (like ERBB2 YVMA mutant) results in sustained GAB1 phosphorylation

How does GAB1 Tyr627 phosphorylation impact different downstream signaling pathways?

GAB1 Tyr627 phosphorylation specifically regulates MAPK pathway activation through SHP2 recruitment. Research using GAB1 mutants demonstrates this relationship:

• GAB1-2F (Y627F/Y659F) mutant: When expressed, blocks phosphorylation of endogenous GAB1 at Tyr-627 and substantially suppresses MAPK phosphorylation in multiple cell lines (BEAS2B/YVMA, T47D/YVMA, H1781) .

• GAB1-3F (Y447F/Y472F/Y589F) mutant: Affects PI3K binding sites and inhibits AKT activation differentially across cell lines:

  • Blocks AKT activation nearly completely in BEAS2B/YVMA cells

  • Reduces AKT activation to ~30% in T47D/YVMA cells

  • Does not impair AKT activation in H1781 cells

• GAB1-5F (combining all mutations): Blocks both pathways in most contexts .

This demonstrates that GAB1 phosphorylation sites have distinct and sometimes cell type-specific roles in pathway activation, with Tyr627 being critical for MAPK signaling across diverse cellular contexts.

What is the relationship between oncogenic ERBB2 mutations and GAB1 Tyr627 phosphorylation?

Oncogenic ERBB2 mutations, particularly the YVMA insertion mutant found in lung cancers, dramatically affect GAB1 Tyr627 phosphorylation through altered kinase specificity:

• Increased phosphorylation: ERBB2 YVMA or ERBB2 G776VC expression in cells results in significantly increased phosphorylation of GAB1 compared to wild-type ERBB2 .

• Altered substrate specificity: Kinetic studies revealed that ERBB2 YVMA has remarkably increased catalytic efficiency for GAB1 phosphorylation sites:

This represents an extraordinary ~150-fold increase in catalytic efficiency for GAB1 Tyr627 phosphorylation by the mutant kinase .

• Biological significance: In transgenic mice expressing ERBB2 YVMA, intrabronchial carcinomas show strong positive staining for phospho-GAB1 Tyr-627, while normal lung tissues are negative. This coincides with activation of AKT and MAPK in these carcinomas .

How can phospho-GAB1 (Tyr627) be used as a biomarker in cancer research?

Phospho-GAB1 (Tyr627) has potential as a biomarker in cancer research based on several lines of evidence:

• Diagnostic applications: Immunohistochemical staining for phospho-GAB1 Tyr-627 successfully identifies ERBB2 YVMA-driven lung carcinomas in transgenic mice, distinguishing them from normal lung tissue .

• Therapeutic response monitoring: Since GAB1 phosphorylation is a direct consequence of oncogenic kinase activity, monitoring phospho-GAB1 (Tyr627) levels could help assess response to targeted therapies.

• Functional significance: GAB1 phosphorylation is critical for:

  • ERBB2 mutant-induced transformation of BEAS2B cells

  • Proliferation of H1781 lung cancer cells

  • Survival of T47D cells in serum-free conditions

These findings suggest that phospho-GAB1 (Tyr627) could serve as both a biomarker and potential therapeutic target in cancers with hyperactive receptor tyrosine kinase signaling.

What are the key differences between various commercially available phospho-GAB1 (Tyr627) antibodies?

When selecting a phospho-GAB1 (Tyr627) antibody, researchers should consider several factors that differentiate commercial options:

• Antibody type:

  • Monoclonal antibodies: Available from Cell Signaling Technology (C32H2 clone) and Invitrogen (T.921.2 clone) , offering high specificity

  • Polyclonal antibodies: Available from various suppliers including Abcam and Affinity Biosciences

• Species reactivity:

  • Human: All antibodies detect human phospho-GAB1 (Tyr627)

  • Mouse: Some antibodies are validated for mouse samples

  • Rat: Some antibodies are predicted to work with rat samples based on sequence homology

• Validated applications:

  • Western blot: All antibodies

  • ICC/IF: Selected antibodies

  • IHC: Some antibodies have been used successfully in published research

  • ELISA: Specialized kits available

• Storage conditions: Typically -20°C in buffers containing glycerol and protein stabilizers

What experimental controls should be included when studying GAB1 Tyr627 phosphorylation?

Robust experimental design for studying GAB1 Tyr627 phosphorylation should include multiple controls:

• Positive controls:

  • EGF-treated cells: Known to induce GAB1 Tyr627 phosphorylation

  • Cells expressing constitutively active kinases (e.g., ERBB2 YVMA)

• Negative controls:

  • Untreated/starved cells: Baseline phosphorylation levels

  • Phosphatase treatment: To confirm phospho-specificity of antibody

  • Peptide competition: Using the immunizing phosphopeptide to block antibody binding

• Genetic controls:

  • GAB1 knockdown cells: To verify antibody specificity

  • GAB1 Y627F mutant-expressing cells: To confirm phospho-site specificity

  • Normal rabbit IgG: To control for non-specific binding in immunostaining

• Pathway controls:

  • Kinase inhibitors: To confirm upstream regulators

  • Pathway-specific inhibitors: To establish relationships between GAB1 phosphorylation and downstream effects

How can quantitative analysis of GAB1 Tyr627 phosphorylation be performed?

For quantitative analysis of GAB1 Tyr627 phosphorylation:

• Western blot quantification:

  • Use total GAB1 antibody on stripped membranes or parallel blots

  • Calculate phospho-GAB1/total GAB1 ratio using densitometry

  • Include a standard curve of recombinant phosphorylated protein for absolute quantification

• Cell-based ELISA:

  • High-throughput colorimetric cell-based ELISA kits allow quantification in intact cells

  • Can measure relative amounts of phospho-GAB1 (Tyr627) in cultured cells

  • Useful for screening effects of treatments, inhibitors, or activators

• Phospho-flow cytometry:

  • For single-cell analysis of phosphorylation in heterogeneous populations

  • Requires validation of antibodies for intracellular flow cytometry

• Kinase assays:

  • In vitro kinase assays using purified components and synthetic peptides

  • Allows determination of kinetic parameters (Km, kcat, kcat/Km) as shown in published research :

What are common issues when detecting phospho-GAB1 (Tyr627) and how can they be resolved?

When working with phospho-GAB1 (Tyr627) antibodies, researchers may encounter several challenges:

• Weak or absent signal:

  • Ensure proper stimulation conditions (EGF treatment shows good induction)

  • Use fresh phosphatase inhibitors in all buffers

  • Optimize antibody concentration (try 1:500 to 1:1000 dilution range)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use enhanced chemiluminescence detection systems

• High background:

  • Use BSA instead of milk for blocking

  • Increase washing steps and duration

  • Reduce antibody concentration

  • Pre-clear lysates before immunoprecipitation

• Multiple bands:

  • Verify expected molecular weight (approximately 110 kDa or 77 kDa)

  • Include positive controls with known phosphorylation status

  • Use phosphatase treatment of parallel samples to identify specific phospho-bands

• Cell type-specific issues:

  • Different cell lines show variable patterns of GAB1 phosphorylation response

  • BEAS2B, T47D, and H1781 cells have documented phospho-GAB1 (Tyr627) responses

How does GAB1 Tyr627 phosphorylation compare with other GAB1 phosphorylation sites?

GAB1 contains multiple phosphorylation sites with distinct functions and kinetic properties:

• Functional differences:

  • Tyr-627 and Tyr-659: Essential for SHP2 association and MAPK activation

  • Tyr-447, -472, and -589: Required for binding to p85 subunit of PI3K and AKT signaling

• Kinetic parameters with ERBB2 kinases:

This data shows that Tyr-627 has the highest catalytic efficiency (k_cat/K_m) among GAB1 phosphorylation sites, both with wild-type ERBB2 and especially with the YVMA mutant .

• Structural context:

  • The sequence surrounding Tyr-627 (PKGDKQVE YLDLDLDSG) likely contributes to its preferential phosphorylation by mutant ERBB2

  • This highlights the importance of both the phosphorylation site and its structural context in determining kinase-substrate interactions

How can phospho-GAB1 (Tyr627) analysis contribute to cancer therapeutic development?

Analysis of phospho-GAB1 (Tyr627) offers several opportunities for cancer therapeutic development:

• Biomarker for kinase inhibitor efficacy:

  • Since GAB1 Tyr627 phosphorylation directly results from upstream kinase activity, monitoring this phosphorylation could indicate therapeutic response

  • This is particularly relevant for ERBB2-targeted therapies in lung cancer models expressing ERBB2 YVMA

• Therapeutic target validation:

  • Research shows that expression of GAB1 mutants (GAB1-2F, GAB1-5F) that cannot be phosphorylated at Tyr627:

    • Blocks ERBB2 YVMA-induced transformation of BEAS2B cells

    • Significantly reduces proliferation of H1781 lung cancer cells

    • Inhibits survival of T47D/YVMA cells in serum-free conditions

  • These findings validate the GAB1-SHP2 signaling axis as a potential therapeutic target

• Drug discovery applications:

  • High-throughput cell-based ELISA assays for phospho-GAB1 (Tyr627) can screen for compounds that inhibit this phosphorylation

  • Such screens might identify compounds that indirectly target mutant ERBB2 or other oncogenic kinases

• Combination therapy rationale:

  • Understanding the differential roles of GAB1 phosphorylation sites in activating MAPK vs. PI3K/AKT pathways provides rationale for combination therapies targeting both pathways in ERBB2-driven cancers

What fundamental questions about GAB1 Tyr627 phosphorylation remain unanswered?

Despite significant advances, several important questions about GAB1 Tyr627 phosphorylation remain to be addressed:

• Temporal dynamics:

  • How quickly does GAB1 Tyr627 phosphorylation occur after receptor activation?

  • What is the half-life of phosphorylated GAB1, and which phosphatases regulate its dephosphorylation?

• Spatial organization:

  • Does phospho-GAB1 (Tyr627) localize to specific subcellular compartments?

  • How does membrane recruitment of GAB1 affect its phosphorylation at Tyr627?

• Pathway crosstalk:

  • How does phosphorylation at Tyr627 influence other GAB1 phosphorylation sites?

  • Are there compensatory mechanisms when Tyr627 phosphorylation is blocked?

• Therapeutic resistance:

  • Can alterations in GAB1 phosphorylation mediate resistance to targeted therapies?

  • Would direct inhibition of the GAB1-SHP2 interaction overcome resistance to upstream kinase inhibitors?

• Clinical relevance:

  • Does phospho-GAB1 (Tyr627) status correlate with patient outcomes or therapeutic response in human cancers?

  • Could phospho-GAB1 (Tyr627) serve as a companion diagnostic for selecting patients likely to respond to specific targeted therapies?